Eli Lilly (LLY Quick QuoteLLY - Free Report) reported $11.3 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 36%. EPS of $3.92 for the same period compares to $2.11 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $9.83 billion, representing a surprise of +14.99%. The company delivered an EPS surprise of +48.48%, with the consensus EPS estimate being $2.64.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Lilly performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Cyramza (Ramucirumab /IMC-1121B) - US

  : $116.10 million compared to the $119.78 million average estimate based on four analysts. The reported number represents a change of +1% year over year.

• Net Sales- International-Humalog [$M]

  : $196.90 million versus the four-analyst average estimate of $198.53 million. The reported number represents a year-over-year change of -6.5%.

• Net Sales- International-Forteo [$M]

  : $38.50 million versus the four-analyst average estimate of $42.90 million. The reported number represents a year-over-year change of -23.9%.

• Net Sales- International-Alimta [$M]

  : $21.40 million versus $28.12 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -50.4% change.

• Net Sales- Cyramza (Ramucirumab /IMC-1121B)- Total

  : $248.90 million compared to the $252.22 million average estimate based on four analysts. The reported number represents a change of -4.4% year over year.

• Net Sales- Humulin [$M]

  : $223.60 million versus $184.50 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +8.9% change.

• Net Sales- Humalog [$M]

  : $631.60 million versus $383.68 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +43.4% change.

• Net Sales- Forteo [$M]

  : $69.90 million versus the four-analyst average estimate of $107.27 million. The reported number represents a year-over-year change of -52.8%.

• Net Sales- Erbitux [$M]

  : $155.80 million versus the four-analyst average estimate of $162.77 million. The reported number represents a year-over-year change of -4.1%.

• Net Sales- Alimta [$M]

  : $33.90 million compared to the $37.38 million average estimate based on four analysts. The reported number represents a change of -44.3% year over year.

• Net Sales- Oncology [$M]

  : $2.16 billion versus the four-analyst average estimate of $2.04 billion. The reported number represents a year-over-year change of +29.2%.

• Net Sales- Neurosciences

  : $339.50 million versus the four-analyst average estimate of $287.50 million. The reported number represents a year-over-year change of -12.3%.

View all Key Company Metrics for Lilly here>>>

Shares of Lilly have returned -17.8% over the past month versus the Zacks S&P 500 composite's -6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.